vs

Side-by-side financial comparison of Lineage Cell Therapeutics, Inc. (LCTX) and Sound Financial Bancorp, Inc. (SFBC). Click either name above to swap in a different company.

Sound Financial Bancorp, Inc. is the larger business by last-quarter revenue ($9.5M vs $6.6M, roughly 1.4× Lineage Cell Therapeutics, Inc.). On growth, Lineage Cell Therapeutics, Inc. posted the faster year-over-year revenue change (130.4% vs 1.5%). Sound Financial Bancorp, Inc. produced more free cash flow last quarter ($7.0M vs $-5.3M). Over the past eight quarters, Lineage Cell Therapeutics, Inc.'s revenue compounded faster (113.9% CAGR vs 5.5%).

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to eithe...

U.S. Bancorp is an American multinational banking institution headquartered in Minneapolis, Minnesota and incorporated in Delaware. It is the 5th-largest bank in the United States as of 2025. As the largest bank in the Midwestern United States, it is considered systemically important by the Financial Stability Board. It is the parent company of its primary operating entity, U.S. Bank National Association, which does business as U.S. Bank. The company provides banking, investment, mortgage, tr...

LCTX vs SFBC — Head-to-Head

Bigger by revenue
SFBC
SFBC
1.4× larger
SFBC
$9.5M
$6.6M
LCTX
Growing faster (revenue YoY)
LCTX
LCTX
+128.9% gap
LCTX
130.4%
1.5%
SFBC
More free cash flow
SFBC
SFBC
$12.3M more FCF
SFBC
$7.0M
$-5.3M
LCTX
Faster 2-yr revenue CAGR
LCTX
LCTX
Annualised
LCTX
113.9%
5.5%
SFBC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
LCTX
LCTX
SFBC
SFBC
Revenue
$6.6M
$9.5M
Net Profit
$851.0K
Gross Margin
Operating Margin
-99.1%
27.1%
Net Margin
12.9%
Revenue YoY
130.4%
1.5%
Net Profit YoY
126.0%
EPS (diluted)
$0.00
$0.87

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LCTX
LCTX
SFBC
SFBC
Q4 25
$6.6M
$9.5M
Q3 25
$3.7M
$9.8M
Q2 25
$2.8M
$10.4M
Q1 25
$1.5M
$9.2M
Q4 24
$2.9M
$9.4M
Q3 24
$3.8M
$9.1M
Q2 24
$1.4M
$8.6M
Q1 24
$1.4M
$8.6M
Net Profit
LCTX
LCTX
SFBC
SFBC
Q4 25
$851.0K
Q3 25
$-29.8M
$1.7M
Q2 25
$-30.5M
$2.1M
Q1 25
$-4.1M
$1.2M
Q4 24
$-3.3M
Q3 24
$-3.0M
$1.2M
Q2 24
$-5.8M
$795.0K
Q1 24
$-6.5M
$770.0K
Gross Margin
LCTX
LCTX
SFBC
SFBC
Q4 25
Q3 25
Q2 25
Q1 25
97.6%
Q4 24
94.6%
Q3 24
99.0%
Q2 24
96.9%
Q1 24
93.2%
Operating Margin
LCTX
LCTX
SFBC
SFBC
Q4 25
-99.1%
27.1%
Q3 25
-102.9%
21.3%
Q2 25
-715.4%
24.5%
Q1 25
-433.1%
15.9%
Q4 24
-178.2%
24.6%
Q3 24
-101.6%
15.6%
Q2 24
-416.7%
11.4%
Q1 24
-461.3%
10.9%
Net Margin
LCTX
LCTX
SFBC
SFBC
Q4 25
12.9%
Q3 25
-809.0%
17.3%
Q2 25
-1101.8%
19.8%
Q1 25
-275.6%
12.7%
Q4 24
-114.1%
Q3 24
-80.3%
12.7%
Q2 24
-409.1%
9.2%
Q1 24
-453.0%
9.0%
EPS (diluted)
LCTX
LCTX
SFBC
SFBC
Q4 25
$0.00
$0.87
Q3 25
$-0.13
$0.66
Q2 25
$-0.13
$0.79
Q1 25
$-0.02
$0.45
Q4 24
$0.00
$0.74
Q3 24
$-0.02
$0.45
Q2 24
$-0.03
$0.31
Q1 24
$-0.04
$0.30

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LCTX
LCTX
SFBC
SFBC
Cash + ST InvestmentsLiquidity on hand
$55.8M
$138.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$44.5M
$109.4M
Total Assets
$112.6M
$1.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LCTX
LCTX
SFBC
SFBC
Q4 25
$55.8M
$138.5M
Q3 25
$40.5M
$101.2M
Q2 25
$42.3M
$102.5M
Q1 25
$47.9M
$131.5M
Q4 24
$47.8M
$43.6M
Q3 24
$32.7M
$148.9M
Q2 24
$38.5M
$135.1M
Q1 24
$43.6M
$138.0M
Stockholders' Equity
LCTX
LCTX
SFBC
SFBC
Q4 25
$44.5M
$109.4M
Q3 25
$22.0M
$107.5M
Q2 25
$48.4M
$106.0M
Q1 25
$79.0M
$104.4M
Q4 24
$78.4M
$103.7M
Q3 24
$66.2M
$102.2M
Q2 24
$68.3M
$101.3M
Q1 24
$72.4M
$101.0M
Total Assets
LCTX
LCTX
SFBC
SFBC
Q4 25
$112.6M
$1.1B
Q3 25
$89.6M
$1.1B
Q2 25
$90.8M
$1.1B
Q1 25
$111.8M
$1.1B
Q4 24
$113.2M
$993.6M
Q3 24
$96.6M
$1.1B
Q2 24
$102.8M
$1.1B
Q1 24
$108.5M
$1.1B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LCTX
LCTX
SFBC
SFBC
Operating Cash FlowLast quarter
$-4.9M
$7.2M
Free Cash FlowOCF − Capex
$-5.3M
$7.0M
FCF MarginFCF / Revenue
-79.9%
73.4%
Capex IntensityCapex / Revenue
6.0%
1.8%
Cash ConversionOCF / Net Profit
-5.73×
TTM Free Cash FlowTrailing 4 quarters
$-19.4M
$12.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LCTX
LCTX
SFBC
SFBC
Q4 25
$-4.9M
$7.2M
Q3 25
$-3.6M
$3.8M
Q2 25
$-5.5M
$-494.0K
Q1 25
$-4.9M
$1.9M
Q4 24
$-6.3M
$2.9M
Q3 24
$-5.8M
$3.3M
Q2 24
$-5.2M
$-4.0M
Q1 24
$-5.8M
$3.5M
Free Cash Flow
LCTX
LCTX
SFBC
SFBC
Q4 25
$-5.3M
$7.0M
Q3 25
$-3.6M
$3.8M
Q2 25
$-5.6M
$-518.0K
Q1 25
$-5.0M
$1.8M
Q4 24
$-6.7M
$2.9M
Q3 24
$-5.9M
$3.2M
Q2 24
$-5.2M
$-5.6M
Q1 24
$-5.8M
$1.9M
FCF Margin
LCTX
LCTX
SFBC
SFBC
Q4 25
-79.9%
73.4%
Q3 25
-98.6%
38.3%
Q2 25
-200.8%
-5.0%
Q1 25
-331.8%
19.8%
Q4 24
-234.0%
30.4%
Q3 24
-156.1%
35.5%
Q2 24
-371.2%
-65.4%
Q1 24
-403.1%
22.2%
Capex Intensity
LCTX
LCTX
SFBC
SFBC
Q4 25
6.0%
1.8%
Q3 25
0.3%
0.4%
Q2 25
0.5%
0.2%
Q1 25
6.5%
0.4%
Q4 24
12.7%
0.8%
Q3 24
3.0%
0.5%
Q2 24
3.6%
18.7%
Q1 24
2.6%
19.0%
Cash Conversion
LCTX
LCTX
SFBC
SFBC
Q4 25
-5.73×
Q3 25
2.24×
Q2 25
-0.24×
Q1 25
1.59×
Q4 24
Q3 24
2.84×
Q2 24
-5.05×
Q1 24
4.57×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LCTX
LCTX

Collaboration Revenues$6.3M95%
Other$345.0K5%

SFBC
SFBC

Segment breakdown not available.

Related Comparisons